Neurorehabilitation News

Patients with posttraumatic refractory intracranial hypertension treated with decompressive craniectomy showed reduced mortality and improved recovery at 24 months compared with standard care, per a study published in JAMA Neurology.

Biopharmaceutical company DiaMedica Therapeutics Inc. announced that the FDA placed a clinical hold on its phase 2/3 ReMEDy2 trial of a synthetic protein therapy for treatment of acute ischemic stroke.

While well tolerated, balovaptan did not improve socialization and communication difficulties in young persons with autism spectrum disorder compared with placebo, according to results of a clinical trial published in JAMA Psychiatry.

Analyzing clinical phenotypes of race, ethnicity and sex, as well as history of concussions and depression, were crucial in determining risk for suicide attempts among youth in the United States, a study showed in JAMA Network Open.

Antibodies produced in response to COVID-19 may mistakenly target cells essential to the blood-brain barrier, which can cause bleeds and clots in patients and increase the risk for stroke, researchers reported in Brain.

Gene therapy company uniQure has announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing phase 1/2 clinical trial of AMT-130 for treatment of Huntington’s disease.

Mdoloris, a company specializing in medical pain monitoring technologies, announced its latest device, a bracelet that can record and track the pain and well-being of those who are unable to verbalize or indicate what they are feeling.

Men who experience behavioral changes, such as apathy or hallucinations, are at a faster risk for cognitive decline compared with women, findings published in the Journal of Alzheimer’s Disease showed.

Known for his role as a pilot in “Star Wars,” actor Greg Grunberg has traded in his flight suit to travel cross country to bring awareness to epilepsy care, treatment and patient needs.

Biogen and Happify Health have announced a partnership to provide an artificial intelligence-powered digital solution for people with MS called Kopa, which will offer support for patients through education and engagement.